Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online November 19, 2007
Diabetes 57:584-593, 2008
DOI: 10.2337/db07-1414
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db07-1414v1
57/3/584    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klinger, S.
Right arrow Articles by Thorens, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klinger, S.
Right arrow Articles by Thorens, B.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-{alpha} and DUSP14

Sonia Klinger1,2, Carine Poussin1,2, Marie-Bernard Debril1,2, Wanda Dolci1,2, Philippe A. Halban3, and Bernard Thorens1,2

1 Institute of Physiology, University of Lausanne, Lausanne, Switzerland
2 Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
3 Department of Genetic Medicine and Development, University Medical Center, University Hospital, Geneva, Switzerland

Address correspondence and reprint requests to Bernard Thorens, University of Lausanne, Center for Integrative Genomics, Génopode Building, 1015 Lausanne, Switzerland. E-mail: bernard.thorens{at}unil.ch

Key Words: CREB, cAMP response element-binding protein • CREM, cAMP response element modulator • DMEM, Dulbecco's modified Eagle's medium • ERK1/2, extracellular signal-regulated kinase 1/2 • FACS, fluorescence-activated cell sorter • FBS, fetal bovine serum • GAPDH, glyceraldehyde-3-phosphate dehydrogenase • GFP, green fluorescent protein • GLP-1, glucagon-like peptide-1 • MAPK, mitogen-activated protein kinase • PI 3-kinase, phosphatidylinositol 3-kinase • PKA, protein kinase A

OBJECTIVE—Glucagon-like peptide-1 (GLP-1) is a growth and differentiation factor for mature β-cells and their precursors. However, the overall effect of GLP-1 on increasing β-cell mass in both in vivo and in vitro conditions is relatively small, and augmenting this effect would be beneficial for the treatment or prevention of type 1 and type 2 diabetes. Here, we searched for cellular mechanisms that may limit the proliferative effect of GLP-1 and tested whether blocking them could increase β-cell proliferation.

RESEARCH DESIGN AND METHODS—We examined GLP-1–regulated genes in βTC-Tet cells by cDNA microarrays. To assess the effect of some of these gene on cell proliferation, we reduced their expression using small heterogenous RNA in β-cell lines and primary mouse islets and measured [3H]thymidine or 5'-bromo-2'-deoxyuridine incorporation.

RESULTS—We identified four negative regulators of intracellular signaling that were rapidly and strongly activated by GLP-1: the regulator of G-protein–signaling RGS2; the cAMP response element-binding protein (CREB) antagonists cAMP response element modulator (CREM)-{alpha} and ICERI; and the dual specificity phosphatase DUSP14, a negative regulator of the mitogen-activated protein kinase (MAPK)/extracellular signal–regulated kinase 1/2 (ERK1/2) pathway. We show that knockdown of CREM{alpha} or DUSP14 or expression of a dominant-negative form of DUSP14 increased β-cell line proliferation and enhanced the GLP-1–induced proliferation of primary β-cells.

CONCLUSIONS—Together, our data show that 1) the cAMP/protein kinase A/CREB and MAPK/ERK1/2 pathways can additively control β-cell proliferation, 2) β-cells have evolved several mechanisms limiting GLP-1–induced cellular proliferation, and 3) blocking these mechanisms increases the positive effect of GLP-1 on β-cell mass.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article:

β-Cell Replication by Loosening the Brakes of Glucagon-Like Peptide-1 Receptor Signaling
Frans C. Schuit and Daniel J. Drucker
Diabetes 2008 57: 529-531. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
DiabetesHome page
F. C. Schuit and D. J. Drucker
{beta}-Cell Replication by Loosening the Brakes of Glucagon-Like Peptide-1 Receptor Signaling
Diabetes, March 1, 2008; 57(3): 529 - 531.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.